Chinook Will Soon Have $275m To Advance Kidney Disease Strategy
Company’s Reverse Merger, New Financing Will Fund Four Clinical Trials
Chinook launched less than two years ago to develop precision medicines for chronic kidney diseases and will have three drugs in the clinic in 2021, including a Phase III candidate for IgA nephropathy.
You may also be interested in...
With interim Phase III data showing threefold reduction in proteinuria reduction compared to SOC, Travere plans to seek accelerated US and EU approval of sparsentan in immunoglobulin A nephropathy.
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.
Initial public offerings by Norbert Bischofberger’s start-up as well as Spruce Biosciences and Shattuck Labs bring the US total to 64 in 2020. Also, the pipeline of health care SPACs is growing, Everest and Genor went public in Hong Kong, Idorsia leads recent follow-on offerings and Corbus cuts jobs.